Published in PLoS One on March 14, 2013
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol (1994) 15.93
Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med (1997) 12.26
HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A (2000) 11.51
CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med (2006) 10.34
Diversity considerations in HIV-1 vaccine selection. Science (2002) 9.60
Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature (2004) 9.53
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet (2008) 8.37
Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med (2004) 5.49
Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. AIDS (2003) 5.28
Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol (1998) 5.05
The role of antibodies in HIV vaccines. Annu Rev Immunol (2010) 4.50
Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med (2009) 3.94
HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis (2005) 3.77
Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity (2010) 3.25
Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog (2010) 2.99
Moving to human immunodeficiency virus type 1 vaccine efficacy trials: defining T cell responses as potential correlates of immunity. J Infect Dis (2003) 2.98
Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol (2005) 2.89
Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings. Addiction (2012) 2.45
Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol Methods (2003) 2.28
Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes. J Virol (2007) 2.26
The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci U S A (1997) 2.24
Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses. J Immunol (2006) 1.99
MHC-I-restricted presentation of HIV-1 virion antigens without viral replication. Nat Med (2001) 1.81
Inactivated influenza virus, when presented on dendritic cells, elicits human CD8+ cytolytic T cell responses. J Exp Med (1995) 1.78
HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load. J Virol (2005) 1.76
Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. J Immunol Methods (2003) 1.73
A systematic comparison of methods to measure HIV-1 specific CD8 T cells. J Immunol Methods (2003) 1.73
Functional heterogeneity of cytokines and cytolytic effector molecules in human CD8+ T lymphocytes. J Immunol (2001) 1.68
Intracellular staining for HIV-specific IFN-gamma production: statistical analyses establish reproducibility and criteria for distinguishing positive responses. J Interferon Cytokine Res (2003) 1.23
Host and viral genetic correlates of clinical definitions of HIV-1 disease progression. PLoS One (2010) 1.23
Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. PLoS One (2010) 1.20
Activation of HIV-1 specific CD4 and CD8 T cells by human dendritic cells: roles for cross-presentation and non-infectious HIV-1 virus. AIDS (2002) 1.19
Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1. Vaccine (2011) 1.15
CTL epitope distribution patterns in the Gag and Nef proteins of HIV-1 from subtype A infected subjects in Kenya: use of multiple peptide sets increases the detectable breadth of the CTL response. BMC Immunol (2006) 1.13
In vitro priming recapitulates in vivo HIV-1 specific T cell responses, revealing rapid loss of virus reactive CD4 T cells in acute HIV-1 infection. PLoS One (2009) 1.09
Beyond 51Cr release: New methods for assessing HIV-1-specific CD8+ T cell responses in peripheral blood and mucosal tissues. Clin Exp Immunol (2002) 1.00
Trivalent adenovirus type 5 HIV recombinant vaccine primes for modest cytotoxic capacity that is greatest in humans with protective HLA class I alleles. PLoS Pathog (2011) 1.00
The ins and outs of HIV replication. Cell Microbiol (2005) 1.00
Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3. J Acquir Immune Defic Syndr (2004) 0.95
Evaluation of aldrithiol-2-inactivated preparations of HIV type 1 subtypes A, B, and D as reagents to monitor T cell responses. AIDS Res Hum Retroviruses (2007) 0.94
Poorly soluble peptides can mimic authentic ELISPOT responses. J Immunol Methods (2004) 0.89
The Role of CD4(+) and CD8(+) T Cells in Controlling HIV Infection. Curr Infect Dis Rep (2002) 0.87
Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine. Vaccine (2009) 0.82
HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting. Tissue Antigens (2004) 0.81
Generation and characterization of a defective HIV-1 Virus as an immunogen for a therapeutic vaccine. PLoS One (2012) 0.80
Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol (2011) 2.92
Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci U S A (2002) 2.32
Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr (2004) 2.11
A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl Med (2013) 1.62
Primary human immunodeficiency virus type 1 infection: clinical, virological and immunological characteristics of 75 patients (1997-2003). Enferm Infecc Microbiol Clin (2006) 1.59
Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults. Lancet (2004) 1.59
Metalloproteinases shed TREM-1 ectodomain from lipopolysaccharide-stimulated human monocytes. J Immunol (2007) 1.49
A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med (2003) 1.44
High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control. J Virol (2011) 1.44
Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. J Immunol (2005) 1.34
Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis (2005) 1.32
Clinical implications of disordered magnesium homeostasis in chronic renal failure and dialysis. Semin Dial (2009) 1.20
A new multidisciplinary home care telemedicine system to monitor stable chronic human immunodeficiency virus-infected patients: a randomized study. PLoS One (2011) 1.15
A therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis (2011) 1.15
Therapeutic vaccines against HIV infection. Hum Vaccin Immunother (2012) 1.11
Plasma stromal cell-derived factor (SDF)-1 levels, SDF1-3'A genotype, and expression of CXCR4 on T lymphocytes: their impact on resistance to human immunodeficiency virus type 1 infection and its progression. J Infect Dis (2002) 1.11
Increased alpha-defensins 1-3 production by dendritic cells in HIV-infected individuals is associated with slower disease progression. PLoS One (2010) 1.08
Monocytes from cystic fibrosis patients are locked in an LPS tolerance state: down-regulation of TREM-1 as putative underlying mechanism. PLoS One (2008) 1.08
Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clin J Am Soc Nephrol (2011) 1.06
The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens. J Virol (2011) 1.06
Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection. Clin Infect Dis (2009) 1.05
Group A streptococcal infections in injection drug users in Barcelona, Spain: epidemiologic, clinical, and microbiologic analysis of 3 clusters of cases from 2000 to 2003. Medicine (Baltimore) (2006) 1.05
Prostratin induces HIV activation and downregulates HIV receptors in peripheral blood lymphocytes. Antivir Ther (2004) 1.05
Study of non-Hodgkin's lymphoma mortality associated with industrial pollution in Spain, using Poisson models. BMC Public Health (2009) 1.04
HIV-1 p24(gag) derived conserved element DNA vaccine increases the breadth of immune response in mice. PLoS One (2013) 1.03
Inflammatory responses associated with acute coronary syndrome up-regulate IRAK-M and induce endotoxin tolerance in circulating monocytes. J Endotoxin Res (2007) 1.01
Central nervous system opportunistic infections in developed countries in the highly active antiretroviral therapy era. J Neurovirol (2005) 1.01
Modelling of municipal mortality due to haematological neoplasias in Spain. J Epidemiol Community Health (2007) 1.00
Factors associated with collagen deposition in lymphoid tissue in long-term treated HIV-infected patients. AIDS (2010) 1.00
Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin. Antivir Ther (2008) 0.99
Immunological profile of heterosexual highly HIV-exposed uninfected individuals: predominant role of CD4 and CD8 T-cell activation. J Infect Dis (2007) 0.99
Health impact assessment of a reduction in ambient PM(2.5) levels in Spain. Environ Int (2010) 0.97
Influence of a vaccination schedule on viral load rebound and immune responses in successfully treated HIV-infected patients. AIDS Res Hum Retroviruses (2009) 0.97
Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors. J Acquir Immune Defic Syndr (2002) 0.97
Rate and predictors of non-AIDS events in a cohort of HIV-infected patients with a CD4 T cell count above 500 cells/mm³. AIDS Res Hum Retroviruses (2013) 0.96
Combination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1. J Virol (2012) 0.95
A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. AIDS (2003) 0.95
Dendritic cell based vaccines for HIV infection: the way ahead. Hum Vaccin Immunother (2013) 0.95
The striking geographical pattern of gastric cancer mortality in Spain: environmental hypotheses revisited. BMC Cancer (2009) 0.94
A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism. J Antimicrob Chemother (2010) 0.94
Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients. Antivir Ther (2005) 0.93
Noninvasive diagnosis of hepatic fibrosis in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr (2007) 0.93
Human immature monocyte-derived dendritic cells produce and secrete alpha-defensins 1-3. J Leukoc Biol (2007) 0.93
Psychological stress is associated with high levels of IL-6 in HIV-1 infected individuals on effective combined antiretroviral treatment. Brain Behav Immun (2012) 0.93
4-Phenylcoumarins as HIV transcription inhibitors. Bioorg Med Chem Lett (2005) 0.92
Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals. PLoS One (2011) 0.92
Trends in oral cavity, pharyngeal, oesophageal and gastric cancer mortality rates in Spain, 1952-2006: an age-period-cohort analysis. BMC Cancer (2014) 0.91
Proximity to mining industry and cancer mortality. Sci Total Environ (2012) 0.91
Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS. J Virol (2010) 0.91
Municipal distribution of breast cancer mortality among women in Spain. BMC Cancer (2007) 0.91
Highly active antiretroviral therapy (HAART) modifies the incidence and outcome of visceral leishmaniasis in HIV-infected patients. J Acquir Immune Defic Syndr (2002) 0.90
Effective visible light-activated B-doped and B,N-codoped TiO2 photocatalysts. J Am Chem Soc (2007) 0.89
Inflammatory responses in blood samples of human immunodeficiency virus-infected patients with pulmonary infections. Clin Diagn Lab Immunol (2004) 0.89
The human genome: a multifractal analysis. BMC Genomics (2011) 0.89
Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort. J Acquir Immune Defic Syndr (2006) 0.88
Pleural cancer mortality in Spain: time-trends and updating of predictions up to 2020. BMC Cancer (2013) 0.88
Short communication: CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41. AIDS Res Hum Retroviruses (2014) 0.87
Effect of TNF-alpha genetic variants and CCR5 Delta 32 on the vulnerability to HIV-1 infection and disease progression in Caucasian Spaniards. BMC Med Genet (2010) 0.87
Molecular characterization of heterologous HIV-1gp120 gene expression disruption in mycobacterium bovis BCG host strain: a critical issue for engineering mycobacterial based-vaccine vectors. J Biomed Biotechnol (2010) 0.87
Mixed alkylamido aluminate as a kinetically controlled base. J Am Chem Soc (2008) 0.86
Decreased pregnancy rate after in-vitro fertilization in HIV-infected women receiving HAART. AIDS (2006) 0.86
Opportunistic infections and immune reconstitution inflammatory syndrome in HIV-1-infected adults in the combined antiretroviral therapy era: a comprehensive review. Expert Rev Anti Infect Ther (2015) 0.86
Municipal distribution of ovarian cancer mortality in Spain. BMC Cancer (2008) 0.85
Clinicoimmunological progression and response to treatment of long-term nonprogressor HIV-hepatitis C virus-coinfected patients. AIDS Res Hum Retroviruses (2007) 0.85
Impact of alpha-defensins1-3 on the maturation and differentiation of human monocyte-derived DCs. Concentration-dependent opposite dual effects. Clin Immunol (2009) 0.85
Lung cancer mortality in towns near paper, pulp and board industries in Spain: a point source pollution study. BMC Public Health (2008) 0.85
Phenotype and functional analysis of human monocytes-derived dendritic cells loaded with a carbosilane dendrimer. Biomaterials (2010) 0.85
Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine. Antivir Ther (2011) 0.85
Differential prevalence of the HLA-C -- 35 CC genotype among viremic long term non-progressor and elite controller HIV+ individuals. Immunobiology (2012) 0.85
Dynamics of T cells subsets and lymphoproliferative responses during structured treatment interruption cycles and after definitive interruption of HAART in early chronic HIV type-1-infected patients. AIDS Res Hum Retroviruses (2006) 0.84
HIV-1 upregulates intercellular adhesion molecule-1 gene expression in lymphoid tissue of patients with chronic HIV-1 infection. J Acquir Immune Defic Syndr (2007) 0.84
Effect of genetic variants of CCR2 and CCL2 on the natural history of HIV-1 infection: CCL2-2518GG is overrepresented in a cohort of Spanish HIV-1-infected subjects. J Acquir Immune Defic Syndr (2007) 0.84
Time trends in municipal distribution patterns of cancer mortality in Spain. BMC Cancer (2014) 0.84
Influence of episodes of intermittent viremia ("blips") on immune responses and viral load rebound in successfully treated HIV-infected patients. AIDS Res Hum Retroviruses (2012) 0.84
Adenosine deaminase enhances the immunogenicity of human dendritic cells from healthy and HIV-infected individuals. PLoS One (2012) 0.83
Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: a randomized pilot study. J Acquir Immune Defic Syndr (2004) 0.83
Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C. Antivir Ther (2004) 0.83
Lymphoid tissue collagen deposition in HIV-infected patients correlates with the imbalance between matrix metalloproteinases and their inhibitors. J Infect Dis (2011) 0.82
A population genetics study of Anopheles darlingi (Diptera: Culicidae) from Colombia based on random amplified polymorphic DNA-polymerase chain reaction and amplified fragment lenght polymorphism markers. Mem Inst Oswaldo Cruz (2007) 0.82
Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine. Vaccine (2009) 0.82
Polymorphisms in the interleukin-4 receptor alpha chain gene influence susceptibility to HIV-1 infection and its progression to AIDS. Immunogenetics (2005) 0.82
Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial. AIDS Res Hum Retroviruses (2010) 0.82